Vanguard Group Inc Athira Pharma, Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,556,651 shares of ATHA stock, worth $466,995. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,556,651
Previous 1,613,063
3.5%
Holding current value
$466,995
Previous $725,000
26.62%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ATHA
# of Institutions
62Shares Held
18.8MCall Options Held
17.2KPut Options Held
800-
Perceptive Advisors LLC New York, NY5.4MShares$1.62 Million0.11% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2.78MShares$832,7651.01% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$447,8370.05% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$447,8370.87% of portfolio
-
Black Rock Inc. New York, NY676KShares$202,8730.0% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $11.3M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...